Apollon Wealth Management LLC Buys 3,976 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Apollon Wealth Management LLC grew its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 48.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,172 shares of the pharmaceutical company’s stock after buying an additional 3,976 shares during the quarter. Apollon Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $4,901,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VRTX. Northwest Investment Counselors LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $27,000. Dunhill Financial LLC increased its stake in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $30,000. Finally, Legacy Investment Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals in the third quarter valued at about $33,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on VRTX shares. Barclays lowered their price target on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research report on Friday, December 20th. BMO Capital Markets reduced their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. Canaccord Genuity Group raised their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Piper Sandler decreased their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Finally, Wells Fargo & Company cut Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective on the stock. in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Trading Down 2.5 %

Shares of VRTX stock opened at $469.32 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The stock has a market capitalization of $120.86 billion, a P/E ratio of -235.84, a P/E/G ratio of 1.80 and a beta of 0.41. The firm’s 50 day moving average is $435.87 and its 200 day moving average is $462.68.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.